Stevanato Group signs an agreement with Pfeiffer Vacuum

Stevanato Group will provide biopharma companies with advanced Container Closure Integrity (CCI) analysis and testing protocols by Pfeiffer Vacuum Technologies

Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for combination products and the US-based Pfeiffer Vacuum, specialized in leak testing & CCIT technologies, announced an agreement thanks to which the US Technology Excellence Center, opening in Boston in the second half of 2020, will be providing characterization testing of the container-closure system for the Biopharma industry.

Leveraging the experience of SG Lab, TEC will provide analytical and testing services related to the container closure system, drug delivery devices and a set of customized services for Biopharma Companies’ drug formulation and manufacturing process. An introduction on US SG TEC services was provided at Stevanato Group’s booth A60, in Hall 7.2 at Pharmapack Europe, February 5-6.

Thanks to a highly skilled team in the area of primary container testing and a wide network of partners, TEC will guide biopharma customers in the choice of the best-suited container for their drug as well as guide them in the testing for integration in drug delivery devices as well as device selection.

With offices in Indiana, USA, Pfeiffer Vacuum boasts a unique portfolio of equipment dedicated to the pharmaceutical industry and medical markets. The company was be present at Pharmapack Europe, Hall 1, booth K22, showcasing three different technologies that will be installed at the US-based TEC: the helium mass spectrometry, for MALL testing, the patented and proven Mass Extraction technology able to detect defects as small as 1 μm on glass vials and an Optical Emission Spectroscopy Instrument, to measure leak tightness using a patented process that does not require a tracer gas.

“The TEC-Pfeiffer Vacuum agreement combines our extensive expertise in glass primary packaging testing, acquired through SG Lab, with top-notch CCI testing solutions for the biopharma market. Over the years, biopharma companies have been facing ever stricter standard requirements in terms of reliability of the CCI testing. Adopting Pfeiffer Vacuum technologies will allow us to address the requests for quality, integrity and effectiveness of sensitive drugs, preventing issues such as moisture or oxygen or microbial contamination.” said Abizer Harianawala, Site Leader at Stevanato Group TEC.

“Partnering Pfeiffer Vacuum’s industry leadership in CCIT, acquired through ATC, with Stevanato Group’s superlative experience of the biopharma industry and glass packaging testing is a win-win for both companies as well as packaging suppliers and creates an axis of excellence in parenteral drug packaging.” said Brian Pahl, President, Pfeiffer Vacuum.